IL269321B - Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer - Google Patents

Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer

Info

Publication number
IL269321B
IL269321B IL269321A IL26932119A IL269321B IL 269321 B IL269321 B IL 269321B IL 269321 A IL269321 A IL 269321A IL 26932119 A IL26932119 A IL 26932119A IL 269321 B IL269321 B IL 269321B
Authority
IL
Israel
Prior art keywords
group
formula
polymer
drug
monomer
Prior art date
Application number
IL269321A
Other languages
English (en)
Hebrew (he)
Other versions
IL269321A (en
Inventor
Lonsdale Birkett Stephen
Craig Donohue Andrew
Marina D'souza Asha
Man Yee Ng Sarah
Sulistio Adrian
John Tait Russell
Valade David
Naylor Alan
Watling Jason
Original Assignee
Polyactiva Pty Ltd
Lonsdale Birkett Stephen
Craig Donohue Andrew
Asha Marina Dsouza
Man Yee Ng Sarah
Sulistio Adrian
John Tait Russell
Valade David
Naylor Alan
Watling Jason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/458,546 external-priority patent/US10113033B2/en
Priority claimed from AU2017900888A external-priority patent/AU2017900888A0/en
Application filed by Polyactiva Pty Ltd, Lonsdale Birkett Stephen, Craig Donohue Andrew, Asha Marina Dsouza, Man Yee Ng Sarah, Sulistio Adrian, John Tait Russell, Valade David, Naylor Alan, Watling Jason filed Critical Polyactiva Pty Ltd
Publication of IL269321A publication Critical patent/IL269321A/en
Publication of IL269321B publication Critical patent/IL269321B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/08—Polyhydrazides; Polytriazoles; Polyaminotriazoles; Polyoxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL269321A 2017-03-14 2018-03-14 Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer IL269321B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/458,546 US10113033B2 (en) 2013-03-08 2017-03-14 Polymer conjugate for delivery of a bioactive agent
AU2017900888A AU2017900888A0 (en) 2017-03-14 Biodegradable drug-polymer conjugate
PCT/AU2018/050233 WO2018165710A1 (en) 2017-03-14 2018-03-14 Drug-polymer conjugate

Publications (2)

Publication Number Publication Date
IL269321A IL269321A (en) 2019-11-28
IL269321B true IL269321B (en) 2022-07-01

Family

ID=63521659

Family Applications (2)

Application Number Title Priority Date Filing Date
IL269321A IL269321B (en) 2017-03-14 2018-03-14 Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer
IL269323A IL269323B (en) 2017-03-14 2018-03-14 Biodegradable drug-polymer couple

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL269323A IL269323B (en) 2017-03-14 2018-03-14 Biodegradable drug-polymer couple

Country Status (14)

Country Link
US (2) US11787906B2 (https=)
EP (2) EP3595670A4 (https=)
JP (2) JP7355649B2 (https=)
KR (2) KR102642432B1 (https=)
CN (4) CN110461336A (https=)
AU (2) AU2018233158B2 (https=)
CA (1) CA3054084A1 (https=)
CL (1) CL2019002600A1 (https=)
IL (2) IL269321B (https=)
MX (2) MX2019010837A (https=)
NZ (2) NZ756626A (https=)
SG (2) SG11201907956UA (https=)
WO (2) WO2018165710A1 (https=)
ZA (2) ZA201905589B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
MX2019010837A (es) * 2017-03-14 2019-12-19 Polyactiva Pty Ltd Conjugado biodegradable de farmaco-polimero.
WO2021024041A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Controlled release drug dimers
CA3154867A1 (en) * 2019-09-19 2021-03-25 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
WO2024084056A1 (en) * 2022-10-21 2024-04-25 Etherna Immunotherapies Nv Ionizable lipids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134689A1 (en) * 2013-03-08 2014-09-12 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044797B (it) 1974-10-15 1980-04-21 Ferruti Paolo Alti polimeri contenenti radicali prostaglandinici processo per la loro preparazione e loro impiego
JPH03220201A (ja) 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
JP4419368B2 (ja) 2002-07-25 2010-02-24 小野薬品工業株式会社 プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
MY155629A (en) 2008-10-10 2015-11-13 Polyactiva Pty Ltd Biodegradable polymer-bioactive moiety conjugates
SI2340271T1 (sl) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
US8535655B2 (en) * 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20120130045A1 (en) 2009-06-01 2012-05-24 Ablitech, Inc. Biomolecule-polymer conjugates and methods of making same
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012075117A2 (en) 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
WO2012139164A1 (en) * 2011-04-12 2012-10-18 Polyactiva Pty Ltd Polymer conjugated prostaglandin analogues
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
MY190370A (en) * 2012-06-26 2022-04-18 Polyactiva Pty Ltd Polymer-nsaid conjugate
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
MX2019010837A (es) * 2017-03-14 2019-12-19 Polyactiva Pty Ltd Conjugado biodegradable de farmaco-polimero.
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134689A1 (en) * 2013-03-08 2014-09-12 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent

Also Published As

Publication number Publication date
EP3595728A1 (en) 2020-01-22
WO2018165711A1 (en) 2018-09-20
JP2020510690A (ja) 2020-04-09
JP2020510692A (ja) 2020-04-09
WO2018165710A1 (en) 2018-09-20
JP7204661B2 (ja) 2023-01-16
IL269323A (en) 2019-11-28
CA3054084A1 (en) 2018-09-20
BR112019018914A2 (pt) 2020-06-30
KR102642432B1 (ko) 2024-02-28
CN120919337A (zh) 2025-11-11
AU2018233158A1 (en) 2019-09-12
KR20190124243A (ko) 2019-11-04
CN110662561A (zh) 2020-01-07
ZA201906133B (en) 2021-04-28
CN110461336A (zh) 2019-11-15
US11787906B2 (en) 2023-10-17
CA3054328A1 (en) 2018-09-20
US20240247106A1 (en) 2024-07-25
AU2018233159B8 (en) 2024-08-01
AU2018233159A1 (en) 2019-09-12
AU2018233159B2 (en) 2024-05-02
US12503553B2 (en) 2025-12-23
CL2019002600A1 (es) 2020-04-03
EP3595670A4 (en) 2021-05-12
KR20190123776A (ko) 2019-11-01
CN120919336A (zh) 2025-11-11
IL269323B (en) 2022-07-01
IL269321A (en) 2019-11-28
MX2019010904A (es) 2019-12-09
SG11201907956UA (en) 2019-09-27
SG11201907931WA (en) 2019-09-27
JP7355649B2 (ja) 2023-10-03
KR102642433B1 (ko) 2024-02-28
AU2018233158B2 (en) 2024-04-11
NZ756626A (en) 2022-10-28
ZA201905589B (en) 2020-07-29
EP3595670A1 (en) 2020-01-22
NZ757356A (en) 2022-10-28
AU2018233159C1 (en) 2025-01-02
AU2018233159A8 (en) 2024-08-01
US20200123322A1 (en) 2020-04-23
MX2019010837A (es) 2019-12-19
EP3595728A4 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
IL269321B (en) Drug-polymer conjugation that includes a prostaglandin analog conjugated to a polytriazole polymer
JP6509746B2 (ja) 生物活性剤を送達するためのポリマーコンジュゲート
JP7337898B2 (ja) 生物活性剤を含むポリマーコンジュゲート
Cooper et al. Injectable dendrimer hydrogel delivers Melphalan in both conjugated and free forms for retinoblastoma
US11207417B2 (en) Drug-polymer conjugate
US11696955B2 (en) Drug-polymer conjugate
CA3054328C (en) Drug-polymer conjugate
BR112019018914B1 (pt) Conjugado de polímero-prostaglandina e conjugado de monômeroprostaglandina